Observational studyCancer medicine2018
Preliminary results of proton radiotherapy for pediatric rhabdomyosarcoma: a multi-institutional study in Japan.
Observational study in Cancer medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Systematic review and meta-analysis of photon radiotherapy versus proton beam therapy for pediatric rhabdomyosarcoma: TRP-rhabdomyosarcoma 2024.International journal of clinical oncology · 2025Pooled it
- Efficacy and safety of proton beam therapy for rhabdomyosarcoma: a systematic review and meta-analysis.Radiation oncology (London, England) · 2023Pooled it
- Alveolar Rhabdomyosarcoma of Nasopharynx and Paranasal Sinuses in Children Diagnosis and Treatment-Review of the Literature and Case Report.Medicina (Kaunas, Lithuania) · 2025Review
- Clinical Insight on Proton Therapy for Paediatric Rhabdomyosarcoma.Cancer management and research · 2023Review
- Case Report: A 13-year-old adolescent diagnosed as malignant phyllodes tumor combined with rhabdomyosarcoma differentiation.Frontiers in oncology · 2023Article
- Flourish of Proton and Carbon Ion Radiotherapy in China.Frontiers in oncology · 2022Review
- A Critical Review of Radiation Therapy: From Particle Beam Therapy (Proton, Carbon, and BNCT) to Beyond.Journal of personalized medicine · 2021Review
- Proton beam therapy with concurrent chemotherapy is feasible in children with newly diagnosed rhabdomyosarcoma.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2021Article
- Impact on dose distribution and volume changes of a bioabsorbable polyglycolic acid spacer during chemo-proton therapy for a pediatric Ewing sarcoma.Journal of radiation research · 2020Article
- Paediatric proton therapy.The British journal of radiology · 2020Review
- Proton therapy in the most common pediatric non-central nervous system malignancies: an overview of clinical and dosimetric outcomes.Italian journal of pediatrics · 2019Review
- Preliminary results of proton radiotherapy for pediatric rhabdomyosarcoma: a multi-institutional study in Japan.Cancer medicine · 2018Observational
- Prognostic factors for postoperative survival among patients with rhabdomyosarcoma of the limbs.Cancer management and research · 2018Article
- Evaluation of clinical efficacy of Chemotherapy for Rhabdomyosarcoma in children.Pakistan journal of medical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate preliminary results of proton radiotherapy (PRT) for pediatric patients with rhabdomyosarcoma (RMS). From 1987 to 2014, PRT was conducted as initial radiotherapy in 55 patients (35 males, 20 females, median age 5 years, range 0-19) with RMS at four institutes in Japan. Thirty-one, 18, and six patients had embryonal, alveolar, and other RMS, respectively. One, 11, 37, and six patients were in IRSG groups I, II, III, and IV, respectively, and the COG risk group was low, intermediate, and high for nine, 39, and seven patients, respectively. The irradiation dose was 36-60 GyE (median: 50.4 GyE). The median follow-up period was 24.5 months (range: 1.5-320.3). The 1- and 2-year overall survival rates were 91.9% (95% CI: 84.3-99.5%) and 84.8% (95% CI 75.2-94.3%), respectively, and these rates were 100% and 100%, 97.1% and 90.1%, and 57.1% and 42.9% for COG low-, intermediate-, and high-risk groups, respectively. There were 153 adverse events of Grade ≥3, including 141 hematologic toxicities in 48 patients (87%) and 12 radiation-induced toxicities in nine patients (16%). Proton-specific toxicity was not observed. PRT has the same treatment effect as photon radiotherapy with tolerable acute radiation-induced toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.